Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation.
Third Harmonic Bio's mission is to advance the treatment paradigm for allergy and mast cell-mediated diseases with our first-in-class oral therapy, THB001.
Third Harmonic Bio was founded in 2019 by Atlas Venture (Michael Gladstone). The company is headquartered in Cambridge, Massachusetts.
Third Harmonic's KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.
THB's lead product candidate, THB001, is the first highly selective, oral small-molecule KIT inhibitor to enter clinical development. THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.
Third Harmonic Bio is backed by Atlas Venture, General Atlantic, OrbiMed, BVF Partners, Boxer Capital, RA Capital, RTW, Deep Track Capital, and others. The company raised $105M in Series B round on Feb 16, 2022. This brings Third Harmonic Bio's total funding to $155M to date.